Literature DB >> 12539546

Establishment of in vitro cellular model predicting histocompatibility in allograft.

Y Hao1, X Wu, Z Liang, P Xiong, X Jiang, F Gong.   

Abstract

A novel in vitro cellular model producting recipient-donor histocompatibility in allograft was developed to select the donor validity. Fifteen couples of blood samples of donor and recipient in human BMT were examined using the model, and skin allograft in mice was performed to test the model. The results showed that the less the differences of histocompatibility evaluated by the model were, the later GVHR in human BMT occurred and the longer the survival time of skin allografts in mice. It was suggested that the model could be used to predict correctly histocompatibility between donor and recipient.

Entities:  

Mesh:

Year:  2001        PMID: 12539546     DOI: 10.1007/BF02886555

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  4 in total

Review 1.  Much ado about minor histocompatibility antigens.

Authors:  E Simpson; D Roopenian; E Goulmy
Journal:  Immunol Today       Date:  1998-03

2.  The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism.

Authors:  J M den Haan; L M Meadows; W Wang; J Pool; E Blokland; T L Bishop; C Reinhardus; J Shabanowitz; R Offringa; D F Hunt; V H Engelhard; E Goulmy
Journal:  Science       Date:  1998-02-13       Impact factor: 47.728

3.  Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease.

Authors:  E Behar; N J Chao; D D Hiraki; S Krishnaswamy; B W Brown; J L Zehnder; F C Grumet
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

4.  Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.

Authors:  J F Lacerda; M Ladanyi; D C Louie; J M Fernandez; E B Papadopoulos; R J O'Reilly
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.